Form D · Biotechnology
Qurasense, Inc.
Menlo Park, CA · CIK 0001845430
Offering snapshot reported Mar 1, 2021 · SEC filing
- Reported sold
- $12.3M Offering amount: $19.3M
- Investors reported
- 43 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 30, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 1, 2021 | Initial | $12,266,023 | No comparison | 43 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-390819
Series A-1, A-2, A-3, A-4, A-5 and A-6 Preferred Stock; Common Stock issuable upon conversion. Total Offering Amount and Total Amount Sold include conversion of outstanding indebtedness in the aggregate amount of $6,268,555.
Source: Form D, filed Mar 1, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Lagier | Director |
| Sara Naseri | Director, Executive |
| Soren Ronne Therkelsen | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
405 El Camino Real, P.O. Box 606
Menlo Park, CA, 94025
Menlo Park, CA, 94025